Related Experiment Videos
Bronchiolitis
1State University of New York Health Science Center at Syracuse.
Insights
Bronchiolitis, a common viral illness in young children, causes airway inflammation and breathing difficulties. Hospitalization is recommended for those with oxygen saturation below 95%, with specific treatments for high-risk infants.
Area of Science:
- Pediatrics
- Infectious Diseases
- Respiratory Medicine
Background:
- Bronchiolitis is a common lower respiratory tract infection in children under two.
- Respiratory syncytial virus (RSV) is the most frequent cause.
- It leads to inflammation and airway obstruction, causing symptoms like cough and wheezing.
Purpose of the Study:
- To outline the clinical presentation and management of bronchiolitis.
- To identify criteria for hospital admission.
- To specify treatment protocols for different risk groups.
Main Methods:
- Clinical observation and assessment of symptoms.
- Pulse oximetry for oxygen saturation measurement.
- Evaluation of patient history for risk factors (e.g., prematurity, congenital heart disease).
Main Results:
- Decreased oxygen saturation (<95%) at rest indicates a need for hospitalization.
- Standard treatment includes humidified oxygen, IV hydration, and nebulized albuterol.
- High-risk infants (e.g., with congenital heart disease, bronchopulmonary dysplasia, prematurity) may require ribavirin.
Conclusions:
- Early reevaluation (24 hours) is advised for infants with mild disease.
- Prompt medical intervention and risk stratification are crucial for managing bronchiolitis.
- Specific antiviral therapy (ribavirin) is reserved for high-risk infants with severe disease.
Abstract:
Bronchiolitis, a lower respiratory tract illness most often caused by respiratory syncytial virus, generally affects children under two years of age, commonly during the winter months. Necrosis of epithelial cells in the small airways leads to inflammation and airway obstruction, causing decreased oxygen saturation, with cough and wheezing. Hospital admission should be considered for children with pulse oximetry levels less than 95 percent at rest. Treatment consists of humidified oxygen, intravenous hydration and administration of nebulized albuterol. Infants with mild disease who are identified early in the course of illness should be reevaluated in 24 hours. Infants with congenital heart disease, bronchopulmonary dysplasia or a history of prematurity, who are at high risk for severe disease, should be treated with ribavirin.